Pubmed Biomarker Relation Odds
(95% CI)		 P-value Description
34731191 TET1 benign and malignancy p<0.001 The TET1 and 5-hmC expression scores were significantly higher in normal endometrium and premalignant endometrial lesions than in ECs.
29799152 ABHD11-AS1 controls and malignancy p<.05 Real‐time PCR revealed the expression of ABHD11‐AS1 was significantly higher in endometrial carcinoma than in normal endometrial tissues
26539494 HE4 hyperplasia VS normal control p<0.05 The strongly positive expression rate of HE4 in the moderate and severe atypical hyperplasia groups was significantly higher than that in the normal endometrium group
34086554 microRNA 21 benign and malignancy 54.93% (95% CI = 42.7 - 66.8) For discriminating benign lesions from tumors the AUC was 0,750 with a sensitivity of 54.93%
26539494 ANXA2 controls and malignancy p<0.05 ANXA2 were expressed in 95.2 % of the the endometrial carcinoma,which were significantly higher than normal endometrium (55.6 %)
26334303 SPAG9 controls and malignancy p=0.037 Scores of the protein expression was significantly higher in EA, compared with CAEH
26308071 AMF/PGI controls and malignancy p<0.01 Normal tissues stained nearly negative for AMF and weakly positive for AMFR，Tumor tissues exhibited strong staining for both AMF and AMFR，
26308071 AMF controls and malignancy p<0.01 AMF mRNA levels were significantly higher in the EC tissues (52 cases) than in the normal endometrium specimens (30 cases)
26308071 AMF controls and malignancy p<0.01 AMF concentration in serum of 15 patients with untreated endometrial cancer and 15 normal women (control group) were examined and we found that there was remarkable increase in AMF secretion in the serum of EC patients
26283007 CDKN2A controls and malignancy OR = 8.39 with 95% CI 4.03-17.45,test for overall effect, Z = 5.69, p<0.00001. CDKN2A hypermethylation was significantly higher in EC than in normal control tissue
26265413 HE4 controls and malignancy p<0.05 Analysing two groups（benign and EAC group） of patients with different histology, there was demonstrated a statistically significant difference，only in HE4, by cut-off 48,5 pmol/l there was achieved sensitivity of 87.8%, specificity of 56.6% and negative predictive value of 81.1%.
26223178 HE4 controls and malignancy HE4 shows a sensitivity of 72.4% and a specificity of 75.4%
29526558 TRIM44 controls and malignancy p<0.001 TRIM44 expression was low in normal tissues and high in EC tissues
26201353 AMF controls and malignancy p<0.001 The mean scores for AMF staining were 4.5 and 0.95 for cancer tissue and normal human endometrium, respectively
26191146 Musashi-1 protein controls and malignancy p=0.0009 Musashi-1 mRNA expression of EAC is 2.8-fold higher than that of normal endometrium
34731191 TET1 benign and malignancy p=0.0037 EC VS normal endometrium and premalignant endometrial lesions
34086554 microRNA 21 benign and malignancy 90.74% (95% CI = 79.7 - 96.9) For discriminating benign lesions from tumors the AUC was 0,750 with a specificity of 90.74%
26191146 Musashi-1 protein discrimination p=0.000 AUC for Musashi-1 is 0.8, which is higher than other clinicopathological factors
26191146 CD133 controls and malignancy p<0.0001 CD133 mRNA expression of EAC is 5.2-fold higher than that of normal endometrium
26191146 Musashi-1 protein discrimination An ROC curve comparison showed that the area under the curve (AUC) was 0.800 for Musashi-1 .
26166558 LSD1 controls and malignancy p<0.001 Compared with normal endometrium and benign endometrial lesion (both P < 0.001), LSD1 was overexpressed in EEA
26132201 CDKN2A MT-EC vs pure low-grade EAC p=0.006 CDKN2A gene were differentially expressed when MT-ECs were compared to pure low-grade EAC:
26132201 H19 MT-EC vs pure low-grade EAC p=0.010 H19 genes were differentially expressed when MT-ECs were compared to pure low-grade EAC:
29516012 visfatin between stage and grade The diagnostic capabilities of visfatin protein in high differentiation (FIGO III and IV) from a lower (FIGO I and II) clinical stage and prognostic degree of cell differentiation (G1 versus G2, G2 versus G3) on the basis of the analysis of the area under the ROC curve are as follows: 0.87, 0.81, and 0.86.
26132201 HOMER2 MT-EC vs pure low-grade EAC p=0.009 HOMER2 genes were differentially expressed when MT-ECs were compared to pure low-grade EAC:
26132201 TNNT1 MT-EC vs pure low-grade EAC p=0.006 TNNT1 gene were differentially expressed when MT-ECs were compared to pure low-grade EAC:
26132201 PAX8 MT-EC vs pure low-grade EAC p=0.035 Lower expression of PAX8 in MT-ECs compared to all pure cases combined
25951350 Enolase-1 controls and malignancy p=0.005 ENO1 protein was highly expressed in 52% ,(52/100) of EC samples and 31.8% (7/22) of EAH samples, while only in 15.0% (3/20) of NE samples, a significantly lower frequency.
34076790 miRNA 27a benign and malignancy 1.000-1.000 p<0.001 This suggests the potential role for miRNA 27 in diferentiating endometrial cancer from healthy females
25951350 Enolase-1 controls and malignancy p<0.001 Compared with NE tissues, EC tissues exhibited higher expression levels of ENO1 mRNA
25874492 Sam68 controls and malignancy p<0.01 Compared with normal endometrial and endometrial atypical hyperplasia tissues, Sam68 significantly elevated in endometrial cancer samples,which was negative or low in 37 cases (38.9 %) and high in 58 cases (61.1 %).
25613390 G9a controls and malignancy p<0.01 An examination of 28 paired endometrial cancer specimens showed a significantly higher G9a expression in tumor tissues
25557364 ARID1A controls and malignancy p=0.024 Complete loss of ARID1A expression was found in 8 of 17 endometrial carcinoma cases (47%) and none of the 16 endometriosis cases (0%)
25511212 Cyclin D1 together with Ki-67 EC and SH p=0.04 Expression profile of Cyclin D1 was compared in paired groups and a statistically significant difference was observed between the results of EC and SH
34099751 ALDH1 early predictor of EC development p=0.012 ALDH1 was also shown to be an early predictor of EC development, suggesting that it can serve as an independent prognostic indicator of patients with endometrial hyperplasia with or without atypia who would progress to cancer
25511212 Cyclin D1 together with Ki-67 SH and AH p=0.03 Expression profile of Cyclin D1 was compared in paired groups and a statistically significant difference was observed between the results of SH and CH
25511212 Cyclin D1 together with Ki-67 CH and AH p=0.02 Expression profile of Cyclin D1 was compared in paired groups and a statistically significant difference was observed between the results of CH and AH
25511212 Cyclin D1 together with Ki-67 SH and AH p=0.00 Expression profile of Cyclin D1 was compared in paired groups and a statistically significant difference was observed between the results of SH and AH
25477298 RAB8A controls and malignancy p<0.05 A significant increase of RAB8A in EC versus healthy controls was observed
25473755 HAND2 discrimination Simple and complex hyperplasia with atypia exhibited moderate to strong Hand2 expression in 8% of cases (1/12) and a loss of expression or weak expression in 92% of cases (11/12).
34076790 miRNA 27a healthy and malignancy For diagnosis of endometrial cancer, the overall accuracy of miRNA 27a relative expression at a cutoff of 0.2872 was surprisingly 100%.
25473755 HAND2 discrimination In endometrioid adenocarcinomas, Hand2 expression was absent in all cases (22/22).
25473755 HAND2 controls and malignancy p≤0.001 There was a statistically significant decrease in stromal expression of Hand2 between benign endometrium when compared with simple and complex hyperplasia with atypia
25473755 HAND2 controls and malignancy p≤0.001 There was a statistically significant decrease in stromal expression of Hand2 between benign endometrium when compared with simple and endometrioid adenocarcinoma .
25355598 HABP1 controls and malignancy p<0.001 HABP1 was overexpressed in endometrial cancer compared with normal endometrium
29353001 mPRα benign and malignancy p<0.0001 The tumor sections showed significantly lower scores for mPRα (65.4% lower expression versus adjacent control endometrium
25355598 HABP1 controls and malignancy p=0.012 HABP1 was overexpressed in endometrial cancer compared with benign endometrial lesion
25329674 miR-27a AUC 95% CI 0.699, 0.927 AUC =0.894 (sensitivity = 0.774, specificity = 0.818)
25329674 miR-15b AUC 95% CI 0.653, 0.882 AUC = 0.768 (sensitivity = 0.742, specificity = 0.697)
25329674 miR-223 AUC 95% CI 0.651, 0.885 AUC =0.768(sensitivity = 0.645, specificity = 0.818)
25329674 CA125 AUC 95% CI 0.614, 0.863 AUC = 0.739(sensitivity = 0.774, specificity = 0.667)
25329674 miR-27a + CA125 AUC/EEC 95% CI, 0.807, 0.980 A stepwise logistic regression analysis (with forward LR method) was applied on the validation data set. miR-27a and CA125 could be combined as a potential classifier for detecting EEC, and the formula of the classifier was as follow: 0.097×CA125+23.931×miR-27a-3.308.AUC of 0.894 ( sensitivity = 0.774, specificity = 0.970)
34076790 miRNA150-5P discrimination AUC=0.982; 0.955-1.009 p<0.001 miRNA150 -5p showed 88.89% sensitivity and 100% specifcity, 100% positive and 78.9% negative predictive values.
25219463 ANXA2 discrimination p=0.005 NEEC (including serous and clear cell carcinomas) presented a 17% elevated ANXA2 expression compared to EEC(mean 231.35 vs. 197.42 histoscore)
25202086 IgA autoantibody against DLDDLD（dihydrolipoamide dehydrogenase） discrimination p=0.002 Anti-DLD IgA antibody in sera from the endometrial cancer patients was significantly higher than those from the healthy donors
25202086 IgA autoantibody against DLDDLD（dihydrolipoamide dehydrogenase） endometrial cancer vs cervical cancer p=0.024 The IgA antibody titer of the endometrial cancer patients was significantly higher than that of the cervical cancer patients
29353001 mPRγ benign and malignancy p=0.0003 The tumor sections showed significantly lower scores for mPRβ (76.4% lower expression versus adjacent control endometrium
24680596 CGRRF1 controls and malignancy p<0.01 CGRRF1 expression was significantly lower in hyperplasia, Grade I, Grade II, Grade III, UPSC, and MMMT tumor tissues compared to that in normal endometrium
24614826 DJ-1 EEC G1-G2 versus the healthy controls and in ESC versus EEC A significant increase in serum DJ-1 levels of EEC G1-G2 versus the healthy controls and in ESC versus EEC patients was observed
24464006 RASSF1 gene methylation controls and malignancy p<0.001 A significant increase of methylation of the RASSF1 gene in endometrial cancer compared to simplex hyperplasia and intact endometrial tissue
24460345 SPAG9 controls and malignancy p<0.001 Median SPAG9 levels in the EC and control groups were 18.3 (range, 12.7-53.8) and 14.1 (range, 4.3-65.3), respectively
24460345 SPAG9 controls and malignancy p<0.001 A cut-off value of 17 ng/ml for SPAG9 predicted presence of malignant endometrium with 74% sensitivity and 83% specificity ,88% positive predictive value (PPV), and 64.5% negative predictive value (NPV) (AUC=0.82)
24455846 CDH1 and ITGB1 gene controls and malignancy CDH1 and ITGB1 gene expression was observed in all examined tissues and was correlated with cancer malignancy (G).
24316923 tumor-associated carbohydrate antigen sTn controls and malignancy p<0.05 There was a significant difference in the value and the positive rate of sTn in the serum between the subjects and the contrasts
33896823 miR-142-3p discrimination 95% CI: 0.611–0.767 AUC=0.689
24316923 tumor-associated carbohydrate antigen sTn controls and malignancy 3P9 combined with 4A6 is better than B72.3 combined with CC49 in the detection of sTn in the serum.
24228101 URI/RMP controls and malignancy（G3） p<0.05 A significantly higher signal intensity in cancerous tissue of all 7 Grade III cases than that of their adjacent endometrial tissue
29353001 mPRγ benign and malignancy p<0.0001 The scores for mPRγ were significantly higher in tumors versus controls (240.8% higher expression
24222154 E-Cadherin discrimination p=0.004 E-Cadherin overexpression was associated with the group of patients exclusively harboring endometrioid tumors
24211402 Serum HE4 discrimination ROC analysis demonstrated that HE4 AUC=0.76
24145649 napsin A clear cell histotype vs endometrial serous carcinomas p<0.0001 Among the evaluable cases, the frequency of ≥1+ napsin A immunoreactivity was significantly higher in CCCs (43/49, 88%) than in endometrial serous carcinomas
24145649 napsin A clear cell histotype vs endometrial serous carcinomas p<0.0001 Among the evaluable cases, the frequency of ≥1+ napsin A immunoreactivity was significantly higher in CCCs (43/49, 88%) than in endometrial endometrioid carcinomas
24145649 napsin A clear cell histotype vs endometrial serous carcinomas 0.88 (95% confidence interval [CI], 0.75-0.95) The sensitivity predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88
24145649 napsin A clear cell histotype vs endometrial serous carcinomas 0.88 (95% confidence interval [CI], 0.75-0.95) Specificite value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88
24145649 napsin A clear cell histotype vs endometrial serous carcinomas 0.91 (95% CI, 0.86-0.96) Negative predictive value of ≥1+ napsin A expression in predicting the consensus clear cell histotype were 0.88
23947899 CyclinD1 discrimination p=0.000 The prognosis of patients were significantly determined between the two groups regarding CyclinD1 staining [log-rank(Mantel-Cox),log-rank(Mantel-Cox), χ2 =12.293
33896823 miR-146a-5p discrimination 95% CI: 0.616– 0.772 AUC=0.694
23818363 hPEBP4 controls and malignancy p=0.0020 The expression of hPEBP4 increased significantly in the cancer group compared to hyperplasia
29348629 calcium sensing receptor (CaSR) benign and malignancy p=0.022 CaSR protein expression in the endometrial epithelial cancer cells exhibited a statistically significant decrease compared to the normal group
23719407 ProExC two groups of malignancy p=0.003 The difference of ProExC expression in the two groups of malignancy was statistically significant
23700142 API discrimination p=0.0068 The AUC for API was significantly larger than that for CA125
23700142 API controls and malignancy (60.0 %, 95 % CI, 43.3-75.1) VS (22.5 %, 95 % CI, 10.1-38.5) API showed a significantly higher sensitivit than that of CA125
23617619 C2GnT1 controls and malignancy p<0.0005 The expression of C2GnT1 was significantly higher in endometrial carcinoma than in normal endometrium(PI = 8.31 ± 15.29 VS PI = 0.52 ± 1.24)
23438672 Visfatin controls and malignancy p<0.05 Serum levels of visfatin were significantly higher in EC patients than in controls
23438672 Visfatin controls and malignancy p=0.001 Visfatin expression was significantly higher in EC tissue than in normal endometrial tissue
23438672 Visfatin tissue and serum p<0.05 Serum visfatin levels were significantly positively correlated with tissue expression of visfatin in EC patients
23372184 hypoxia-inducible factor 1α and TWISTand E-cadherin controls and malignancy p<0.01 The expression of hypoxia-inducible factor 1α and TWIST were markedly increased, whereas E-cadherin was decreased, as lesions progressed from normal endometrium to atypical hyperplasia to carcinoma
23321718 Wnt7a controls and malignancy p<0.001 Wnt7a was overexpressed in endometrial cancer compared with normal endometrium and benign endometrial lesion
33896823 miR-151a-5 discrimination AUC=0.68; 95% CI: 0.601– 0.759 AUC=0.68
29348629 VEGFR3 controls and malignancy p<0.05 In tissue specimens, VEGFR3 was significantly overexpressed in endometrial cancer relative to normal tissues and was immunolocalized to the glandular cells
23257935 ER-α36 controls and malignancy p<0.01 The expression of ER-α36 in endometrial carcinoma tissues was significantly lower than in normal endometrial tissues and atypical hyperplasia
23200913 GRP78 ndometrial cancer vs visceral adipocytes GRP78 expression in visceral adipocytes was detected in 95% of the 179 endometrial cancer patients with analyzable visceral adipocytes.
23179397 HE4 discrimination The specificity of HE4 is 100 % (positive predictive value = 100 %, negative predictive value = 71.52 and 61.31 % considering the two HE4 cutoff, respectively)
23179397 HE4 discrimination The sensitivity of CA125 in detecting endometrial cancer is 19.8 %, whereas the sensitivity of HE4 is 59.4 and 35.6 % for 70 and 150 pmol/L cutoff, respectively.
23096757 HE4 discrimination Setting the specificity at 95 % , the sensitivities in detecting endometrial cancer patients were 66 % for HE4,
22982899 cyclin D1 YWHAE-FAM22 ESS Cyclin D1 immunostaining showed a as a diagnostic marker for YWHAE-FAM22 ESS.(sensitivity of 100% and specificity of 99% )
22982899 cyclin D1 discrimination/ESS cyclin D1 immunostaining showed a as a diagnostic marker for YWHAE-FAM22 ESS(positive and negative predictive values of 80% and 100%)
22945838 YKL-40 uterine myoma VS controls p=0.000 The mean pre-operative serum YKL-40 values were significantly higher than that in the uterine myoma cases and in the healthy women
22945838 YKL-40 controls and malignancy p=0.000 The mean post-operative serum YKL-40 in the 22 EC cases was significantly lower than pre-operative serum YKL-40 levels in these cases
22886632 MMSET controls and malignancy p<0.001 MMSET immunoreactivity was overexpressed in endometrial cancer compared with normal endometrium
29274810 CIP2A controls and malignancy p<0.001 CIP2A expression significantly differed among normal and EAC tissues
33896823 3-miRNA pane discrimination AUC=0.729; 95% CI: 0.580–0.879 AUC=0.729
22784357 fascin controls and malignancy p=0.02 Fascin expression showed a statistically significant difference from the normal group
22729361 Plasma membrane proteomics identifies bone marrow stromal antigen 2 controls and malignancy p<0.0001 The expression of BST2 was more characteristic of 118 endometrial cancer tissues compared with 59 normal endometrial tissue
22729361 Plasma membrane proteomics identifies bone marrow stromal antigen 2 controls and malignancy p<0.0001 There was a significantly stronger positive staining of BST2 in tissue sections from patients with endometrial cancer compared with normal endometrium
22648251 IPO13 controls and malignancy p<0.05 Western blot analysis showed that IPO13 protein is enhanced in endometriosis and endometrial carcinoma versus secretory phase endometrium
22648251 IPO13 endometriosis p<0.05 IPO13 mRNA expressed in endometriosis was increased by about 2-fold over that in secretory phase endometrium
22648251 IPO13 controls and malignancy p<0.05 The expression level of IPO13 protein in endometriosis (0.81±0.17) and endometrial carcinoma (0.94±0.10) was significantly higher than that in the secretory endometrium (0.45±0.10*)
22460089 miR-125b controls and malignancy p<0.05 The invasion of the cells transfected with anti-miR-125b was increased compared with that of the cells transfected with control miR; the trans-membrane cells ranged from 18% and 30%
22378079 Notch-1 controls and malignancy The LI of Notch-1 in endometrial adenocarcinoma was 45.2 ± 7.4%, which was significantly higher than that in normal endometrium.
22378079 Notch-1 discrimination In analysis item 3, the LI of Notch-1 in EGBD was 31.3 ± 8.3%, which was significantly lower than that in endometrial adenocarcinoma.
34306255 GABPA benign and malignancy p<0.001 The GABPA expression was significantly downregulated in EC tissues compared with its expression in normal tissues
29274810 CIP2A benign and malignancy p<0.01 The results showed that CIP2A expression was significantly higher in the EAC than in the NE tissue samples in mRNA level
22146769 SPAG9 controls and malignancy p<0.05 Sperm-associated antigen 9 serum concentration (ng/mL) of patients with endometrial carcinoma is significantly higher than those of the healthy group
33896823 3-miRNA pane discrimination AUC=0.751; 95% CI: 0.645–0.858 AUC=0.751
22146769 SPAG9 controls and malignancy p=0.005 Serum SPAG9 values from the 50 patients with endometrial carcinoma had a median of 11.7305 ng/mL and a range of 2.436 to 60.545; these values were statistically significantly higher than those in the healthy group,and the benign group
22056701 MMP-2 invasive colorectal endometriosis vs superficial peritoneal endometriosis MMP-2 expression was stronger in invasive colorectal endometriosis than in superficial peritoneal endometriosis
22056701 MMP-9  discrimination MMP-2 and MMP-9 showed higher expression in endometrial carcinoma than in endometriosis.
22056701 PCNA discrimination/endometriosis p=0.0008 When colorectal endometriosis was compared to low grade endometrial carcinoma, proliferation detected by PCNA was significantly higher in endometriosis.
21468050 HE4 controls and malignancy FC=2.63, 95% CI: 1.78–3.88 p<0.0001 HE4 mRNA expression was significantly higher in EC compared with NE patients
21468050 HE4 controls and malignancy p=0.03 Endometrial cancers showed markedly increased HE4 positivity as compared with NEs
21181309 PTTG1+PTEN controls and malignancy p<0.001 Loss of expression in PTEN was identified in 12/28 (42.9%), and 87/124 (70.2%) cases with atypical hyperplasia and endometrial carcinoma, respectively, which was statistically significant.
21176560 Hsa-miR-155 controls and malignancy p<0.01 The expression of hsa-miR-155 was (3.9 ± 0.7) in endometrial cancer, which was significantly higher than that in control group
29169184 HER2 among different histologic groups p=0.03 A significant difference in apical staining patterns was observed among different histologic groups. The serous tumours had the highest prevalence of apical HER2 loss (64%) followed by clear cell carcinomas (46%), endometrioid carcinomas (44%), undifferentiated tumours (38%) and carcinosarcomas (33%)
20527231 Glut-1 controls and malignancy Overexpression of Glut-1 was present in 58% of EIN and 71% of endometrioid adenocarcinoma.
19952936 myocardin controls and malignancy Myocardin was expressed in all normal uterine myometrium and in SMTs (even in the regions with epithelioid features) moderately or strongly, at least topically, whereas in endometrium, in ESNs and in ESSs, except in the regions of smooth muscle differentiation, it was negative.
33896823 3-miRNA pane discrimination AUC=0.789; 95% CI: 0.664–0.914 AUC=0.789
19795358 claudins type I and type II Claudin-1 overexpression characterized type II (seropapillary) endometrial carcinoma, while claudin-2 was elevated in type I (endometrioid) carcinoma.
19795358 claudins discrimination Claudins-3 and -4 were elevated in endometrial cancer.
19795358 claudins serous ovarian carcinoma Claudins-3 and -4 were highly expressed in serous ovarian carcinoma.
19424619 DKK1 discrimination p<0.05 DKK1 expression level in EC tissues was significantly lower than that in benign endometrium tissues
19194826 osteopontin controls and malignancy p<0.001 The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls
18797802 SOD controls and malignancy p<0.05 Decreased SOD activities and unchanged SOD protein level in blood of all examined patients in comparison to healthy subjects.
18797802 SOD controls and malignancy p<0.05 Decrease of both SOD activity and level was found in endometrium of patients with hyperplasia simplex, hyperplasia complex and adenocarcinoma in comparison to women with polypus or myoma.
29114696 cancer antigen 15-3 levels low-risk patients vs other patients with ECs) When the groups (low-risk patients vs other patients with ECs) were assessed in the receiver operating characteristic curve analysis in terms of the 25.0 IU/mL cutoff value, the sensitivity was 33.3% and the specificity was 100%.
18797802 SOD controls and malignancy p<0.05 LOOH level was elevated in both tissues of patients with hyperplasiaor adenocarcinoma in comparison to healthy subjects or patients with benign diagnosis.
18682706 TFF3 controls and malignancy p<0.01 By immunohistochemistry, TFF3 protein was significatively more expressed in EEC compared with NE
18682706 TFF3 controls and malignancy p<0.001 Patients harbouring G3-EECs had significantly higher TFF3 serum concentration by ELISA when compared with healthy patients
34556086 IFITM1,CD10, SMA, h-caldesmon endometrial stromal tumor and cellular leiomyoma When all four antibodies were combined for the differential diagnosis (AUC = 0.995)
33781255 Plasma-derived exosomal miR-15a-5p stage I miR-15a-5p alone yielded an AUC value of 0.813 to distinguish EC patients with stage I from healthy subjects.
18565690 H-caldesmon controls and malignancy H-caldesmon was negative in all SSE, positive in all HCL and in one case of LMS.
18565690 Desmin controls and malignancy Desmin expression was found in two SSE, in all HCL and LMS.
18495222 HE4 controls and malignancy p<0.0001 The median CA125 and HE4 serum levels were significantly elevated among all endometrial cancer stages relative to the healthy subjects
18495222 HE4 controls and malignancy p<0.0001 When considering stage I patients alone, the median HE4 levels were each significantly elevated compared with controls 35.4 (18.0 - 127.8) VS 60.5 (1.1 – 1022.1)
18495222 HE4 stage I p=0.0007 Analysis of the ROC-AUC for individual tumor markers revealed that HE4 had a significantly higher ROC-AUC when compared with CA125 in stage I cancers .
28980703 IRAK1 controls and malignancy p<0.01 IRAK1 expression was significantly increased in EC tissues VS normal endometrium tissues
18495222 HE4 cancer stages p=0.0009 Analysis of the ROC-AUC for individual tumor markers revealed that HE4 had a significantly higher ROC-AUC when compared with CA125 in all cancer stages.
18458692 ADAM19 controls and malignancy p<0.001 The expression level of ADAM19 in endometrial cancer tissue was significantly higher than that in normal endometrium
18431720 PTEN controls and malignancy p<0.005 For the 50% cutoff value, EC (P < .0001), LG-EC (P < .0001), and HG-EC (P = .0058) had statistically significant differences compared with proliferative endometrium
18431720 PTEN controls and malignancy p<0.03 For the 50% cutoff value, EC (P = .0004), LG-EC (P = .0003), and HG-EC (P = .0236) had statistically significant differences compared with secretory endometrium .
18431720 PTEN controls and malignancy p<0.002 For the 50% cutoff value, EC (P = .0019) and LG-EC (P = .0015) also had statistically significant differences compared with atrophic endometrium.
33781255 miR-15a-5p and serum tumor markers discrimination The integration of miR-15a-5p and serum tumor markers (CEA and CA125) achieved a higher AUC value of 0.899.
18422745 Midkine (MK) controls and malignancy p<0.001 MK expression was significantly higher in the carcinomas than in normal endometrium
18422745 Midkine (MK) controls and malignancy p=0.01 Serum MK value in patients with cancer was significantly higher than that in the patients with benign diseases
18377423 NDRG1 controls and malignancy p<0.01 The expression of NDRG1 was up-regulated in 5/40 (12.5%), 18/34 (52.94%), and 86/103 (83.5%) normal endometrium, atypical hyperplasia, and endometrial carcinoma cases, respectively .
18377423 PTEN controls and malignancy p<0.01 PTEN expression was significantly decreased in 6/40 (15%), 20/34 (58.82%), and 89/103 (86.41%) normal endometrium, atypical hyperplasia, and endometrial carcinoma cases, respectively
34086554 microRNA 21 benign and malignancy 95% CI = 0.863 - 0.964 p<0.0001 MicroRNA-21 is a potential biomarker for endometrial cancer with an area under the receiver operating characteristic curve of 0.925
17980190 serum p53 antibody (S-p53 Ab) The overall accuracy (kappa value) of S-p53 Ab (0.70) and CA125 (0.71) was almost the same (substantial agreement).
17885673 IMP3 serous carcinoma p<0.0001 There was a significant expression of IMP3 in serous carcinoma as compared to endometrioid adenocarcinoma
17023034 YKL-40 controls and malignancy p<0.0001 Median preoperative YKL-40 value was 137 ng/mL (range, 22-1738 ng/mL) for endometrial cancer patients compared with 28 ng/mL (range, 15-72 ng/mL) for normal healthy subjects
16980945 AIB1 controls and malignancy p=0.007 In endometrial carcinoma, there is a higher expression of AIB1 compared to carcinoma-associated complex atypical hyperplasia
16980945 AIB1 controls and malignancy p<0.001 In endometrial carcinoma, there is a higher expression of AIB1 compared to carcinoma-associated normal endometrium
16892013 GLUT8 controls and malignancy p<0.001 GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium
33660848 IDO benign and malignancy AUC=0.733; 95% CI, 0.602-0.840 p<0.002 Receiver operating characteristic curve analysis revealed that IDO was good predictors of early-stage endometrial cancer early-stage endometrial cancer
16888409 TADG-14/KLK8 proliferative compared to secretory phase endometria p=0.0143 TADG-14/KLK8 mRNA expression levels were significantly higher in proliferative compared to secretory phase endometria
16888409 TADG-14/KLK8 proliferative compared to secretory phase endometria p=0.0002 hK8 was detected in 73.3% (11/15) of endometria with a significantly higher detection rate in the proliferative compared to secretory and atrophic phase endometri
16888409 TADG-14/KLK8 controls and malignancy p=0.0187 High expression of hK8 was found in 61.4% of endometrial carcinomas compared to 35.1% of endometrial tissue samples
28965628 cyclin D1 controls and malignancy p=0.0001 High staining is more common in normal proliferative and secretory endometrium vs serous carcinoma negative staining
16842844 RCAS1 controls and malignancy p<0.05 Uterine cancer patients had significantly higher serum RCAS1 concentrations than did healthy blood donors
16842844 RCAS1 squamous cell p=0.0340 Patients with adenocarcinoma had significantly higher RCAS1 concentrations than did those with squamous cell carcinoma
16820900 Lactoferrin (Lf) endometrioid type carcinoma vs non-endometrioid type A variable expression of Lf was revealed in 43 cases (61%) of EC. Endometrioid type carcinoma showed a significant higher Lf ID-score than non-endometrioid type;
16803534 E-cadherin, alpha-catenin, and beta-catenin endometrioid type carcinoma vs non-endometrioid type p=0.04 Negative E-cadherin expression was more often observed in nonendometrioid endometrial carcinomas (NEECs) than in endometrioid carcinomas(75% versus 43%)
16681769 ERRalpha and ERRgamma controls and malignancy p=0.014 The relative level of ERRgamma mRNA in ERalpha-positive endometrial adenocarcinomas was higher than in normal endometriums
16681769 ERRalpha and ERRgamma controls and malignancy p=0.049andp=0.023 The expression rate and relative level of ERRalpha mRNA in ERalpha-positive endometrial adenocarcinomas were lower than in normal endometriums
16575402 CRBP-1 hyperplasia p<0.0009 CRBP-1 expression was higher in complex atypical compared to simple hyperplasia
33660848 periostin benign and malignancy AUC=0.668;95% CI, 0.533-0.785 p=0.018 Receiver operating characteristic curve analysis revealed that periostin was good predictors of early-stage endometrial cancer
16495475 Haymaker protein discrimination p<0.005 Haymaker protein is highly expressed in epithelial cells of the endometrium of the normal uterus and to a somewhat lesser extent in the mucosa of the normal vagina and cervix, but is poorly expressed or absent in cells of the connective tissue and smooth muscle strata of these organs
16495475 Haymaker protein epithelial cells compared with the stromal cells p<0.001 A higher proportion of the epithelial cells expressed Haymaker, as compared with the stromal cells from the paired gynecological samples with tumor.
28965628 cyclin D1 controls and malignancy p=0.0001 Significantly higher proportion of high score cyclin D1 immunostaining is observed in controls while higher proportion of negative cyclin D1 immunostaining is observed among carcinoma cases
16495475 Haymaker protein epithelium vs connective tissue or smooth muscle p=0.004 The proportion of epithelial cells staining and the intensity of staining were markedly higher in the epithelium than in the connective tissue or smooth muscle
16322283 EIG121 controls and malignancy The expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors).
16322283 EIG121 discrimination EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium.
16311121 Aurora B proliferative phase vs secretory phase p<.0001 In the normal endometrial glandular cells, the nuclear staining of Aurora B was highest in the proliferative phase (PI, 21.6 ± 16.3; Fig. 2, Fig. 3) and was markedly decreased in the secretory phase (PI, 0.6 ± 1.6) with a significant difference
16311121 Aurora B controls and malignancy p<.0001 In endometrial carcinoma, the mean PI for Aurora B in all carcinoma cases was 0.3 ± 0.8, which was significantly lower than that in normal proliferative endometria
16014121 c-FLIP controls and malignancy p<0.01 A semiquantitative analysis of the PCR densitometric data revealed that mean expression levels of c-FLIP mRNA in carcinomas were significantly higher than in normal tissues (0.68 ± 0.22 versus 0.47 ± 0.15)
16014121 c-FLIP controls and malignancy p<0.01 c-FLIP protein expression was significantly higher in neoplastic tissues than in normal tissues
15948123 PTEN discrimination All cases that progressed were PTEN null, indicating that this genotype is capable of further stratifying cancer progression risk in hyperplasias irrespective of histological categorization
33660848 CEA benign and malignancy AUC=0.709; 95% CI, 0.576-0.820 p=0.002 Receiver operating characteristic curve analysis revealed that CEA were good predictors of early-stage endometrial cancer
15867230 Human kallikrein 6 (hK6) USPC p=0.006 Serum and plasma hK6 values in USPC patients (mean ± SE, 6.1 ± 1.1; range, 1.9-15.6) were significantly higher than those in the noncancer
28700435 IFITM1 controls and malignancy p=0.003 The difference in staining between smooth muscle tumors and ESS was statistically significant when considering staining intensity
15867230 Human kallikrein 6 (hK6) USPC p=0.003 Serum and plasma hK6 values in USPC patients (mean ± SE, 6.1 ± 1.1; range, 1.9-15.6) were significantly higher than those in benign group
15661223 Smad7 controls and malignancy p<0.001 Smad7 transcripts in the tumors were over 11-fold elevated on average than in controls
15363194 P53 and C-erbB-2 discrimination p<0.005 The positive rate of P63 in EC was 81.6%, significantly higher than those in EH and BPE
15363194 P63 discrimination The positive rate of P63 in EC was 81.6%, significantly higher than those in EH and BPE
15176219 Hdj1 controls and malignancy Hsp70 and Hdj1 expression was higher in malignant cells than in benign one
15025952 cFLIP controls and malignancy The positive rates of cFLIP expression in normal proliferative samples of endometrium, hyperplastic samples, and endometrial adenocarcinomas were (55.0+/-11.4)%, (72.5+/-7.1)%, and (83.3+/-5.8)%, respectively.
15025282 telomerase controls and malignancy Mean trf lengths became shortened as the normal tissues underwent neoplastic changes
15025282 telomerase controls and malignancy Strong telomerase activity was observed in the proliferative phase of the normal endometrium, endometrial cancers and post-menopausal endometrial hyperplasias compared to normal, secretory and resting phases of the endometrium
14576480 oxytocin receptor controls and malignancy Every ESS was negative for OTR, except in regions of smooth muscle differentiation.OTR was strongly expressed in the myometrium and showed expression pronounced in the surface epithelium during the late proliferative phase and at the time of ovulation, whereas the endometrial stromal cells were negative
33660848 CEA healthy and malignancy p=0.008 Carcinoembryonic antigen (CEA) was significantly higher in the study group than the control group
28700435 IFITM1 controls and malignancy p=0.03 The difference in staining between smooth muscle tumors and ESS was statistically significant when considering staining distribution
12820350 CA-125 controls and malignancy The highest CA-125 reaction was observed in AH III in glandular and luminal cells, which was statistically higher compared to all groups (except glandular cells: proliferative and LS; luminal cells: AH I-II, glandular-cystic polyps).
12819391 endoglin (CD105) CHA and SH (p<0.001 Endoglin showed significant differences between CHA and SH
12819391 endoglin (CD105) CHA and SH VEGF showed significant differences between CHA and SH
12485478 h-caldesmon controls and malignancy p=0.001 Immunoreactivities of highly cellular leiomyoma (HCL) for h-caldesmon were 80.0% (16/20) ,whereas the positive rates of uterine endometrial stromal tumors (EST) were 4.7% (1/21),
12485478 calponin controls and malignancy p=0.001 Immunoreactivities of HCL for calponin were 100% (20/20), whereas the positive rates of EST were 23.8% (5/21).
12485478 CD10 controls and malignancy p=0.001 Immunoreactivities of HCL for CD10 were 0 (0/20),whereas the positive rates of EST were 66.7% (14/21).
12485478 Desmin controls and malignancy p=0.001 Immunoreactivities of HCL for Desmin were 95.0% (19/20) ,whereas the positive rates of EST were 23.8% (5/21).
12485478 smooth muscle actin (SMA) controls and malignancy p=0.001 Immunoreactivities of HCL for SMA were 100% (20/20), respectively, whereas the positive rates of EST were 19.0% (4/21).
12479072 VEGF controls and malignancy p<0.01 The VEGF levels in endometrial cancer and ovarian cancer patients were significantly higher than that in healthy women
11078809 human telomerase reverse transcriptase controls and malignancy p<0.05 Telomerase activity was detected in 34/36 subjects (94.4%) from the CA group and in 3/9 subjects (33.3%) from the NP group
28700435 IFITM1 controls and malignancy p=0.006 The difference in staining between smooth muscle tumors and ESS was statistically significant when considering staining total score
33660848 periostin benign and malignancy p=0.034, Periostin was significantly higher in the study group than the control group
11078809 human telomerase reverse transcriptase controls and malignancy p<0.05 Relative TERT mRNA expression was 0.50 in the CA group, and this was significantly higher compared with the level of 0.10 in the NP group
10999747 Serum soluble fas controls and malignancy p<0.0001 Serum sFas demonstrated a statistically significant elevation relative to levels in normal controls
10920935 telomerase controls and malignancy Of 34 endometrial cancer specimens, 28 (82.4%) showed telomerase activity, whereas 1 of 6 (16.7%) benign endometrial tissues exhibited telomerase activity.
10878548 metallothioneins controls and malignancy p=0.03 A statistically significant difference of MT expression was observed between carcinomas and simple hyperplasias
10841828 PTEN controls and malignancy p=.025 The PTEN mutation rate was 83% (25 of 30) in endometrioid endometrial adenocarcinomas and 55% (16 of 29) in precancers, and the difference in number of mutations was statistically significant .
10831349 CK-20 controls and malignancy By using immunocytochemistry, most carcinomas were found to be negative for CK-20. The sensitivity and specificity rates obtained by using the RT-PCR method were 94.4 and 91%, respectively.
9934583 Ki-S4 PA discrimination p<0.001 The Ki-S4 PA (median value 18.3%) and Ki-S5 PA (median value 25.0%) in endometrial carcinomas showed a signicant correlation (r <0.89)
9865913 PTEN endometrioid histology p=0.004 Mutation of the PTEN gene correlated most closely with endometrioid histology; mutations were seen in only 5% (1 of 21) of serous/clear cell cancers compared with 37% (43 of 115) of endometrioid cancers
9857223 syndecan-1 discrimination The expression of syndecan-1 in 40% of investigated cancers. The most differentiated cancers showed 75% of positively stained specimens, moderately differentiated 40% and poorly differentiated neoplasm did not stain at all.
29936727 neutrophil lymphocyte ratio (NLR) benign, healthy controls and malignancy p=0.048 There was a statistically significant difference between the NLR measurements of the cases from different groups (endometrial adenocarcinoma (group 1), endometrial hyperplasia (group 2) and controls (group 3))
28700435 IFITM1 controls and malignancy p=0.008 The difference in staining pattern was also significant within the various subgroups: low-grade ESS versus leiomyoma
9804252 PP14 controls and malignancy p<0.001 In post-menopausal women, the concentrations of PP14 (mean +/- SEM) in both plasma and flushing were significantly higher in women with endometrial adenocarcinoma (46.9+/-7.5 ng/ml plasma; 3350+/-1711 ng/ml flushing) than in the controls (7.6+/-1.3 ng/ml plasma; 125+/-27 ng/ml flushing) or in women with post-menopausal bleeding and atrophic endometrium (20.4+/-2.1 ng/ml plasma; 453+/-167 ng/ml flushing).
33660848 indoleamine 2,3-dioxygenase (IDO) benign and malignancy p=0.003 IDO levels were significantly higher in the study group than the control group
9804252 PP14 controls and malignancy p<0.001 Concentrations of PP14 in both the plasma and uterine flushings in post-menopausal women were significantly lower than those of control pre-menopausal women.
9804252 PP14 controls and malignancy p<0.001 Concentrations of PP14(both the plasma and uterine flushing) in post-menopausal women with adenocarcinoma were significantly higher than those in women with atrophic endometrium with or without bleeding.
9790796 CK-20 discrimination CK-20 amplification band (370 bp) was obtained with mRNA extracted from endometrial carcinoma cells of 17 of the patients with endometrial carcinoma (sensitivity, 94.4%)
9790796 CK-20 benign endometrial disease CK-20 was negative in 21 patients with benign endometrial disease (specificity, 91.3%)
9473168 melatonin discrimination p<0.001 In addition to the routine hormone analyses, we tested the patients' plasma for differences in melatonin levels. We found a significant correlation between melatonin plasma levels and the presence of endometrial cancer.
9390137 Calretinin discrimination The diagnostic sensitivity of this calretinin immunocytochemical approach reached 100% for the eight malignant mesotheliomas investigated.
9390137 Calretinin discrimination Only 3 of the 13 adenocarcinomas metastatic to the serous membranes included in this study were weakly reactive calretinin, accounting for 81% specificity.
9167896 DNA aneuploidy controls and malignancy Our results show that all normal endometria (n = 62) were exclusively diploid and 2 (2.5%) of 79 endometrial hyperplasias and 22 (68.8%) of 32 endometrial carcinomas were aneuploid.
28700435 IFITM1 controls and malignancy p=0.009 The difference in staining pattern was also significant within the various subgroups: low-grade ESS versus leiomyosarcoma
9167896 SPF controls and malignancy When 9% were used as cut-off values for SPF,13.9% o fendometrial hyperplasia and 50% ,of endometrial carcinoma showed raised levels of the corresponding parameters.
9167896 c-erbB-2 controls and malignancy When 3.2 HNU (Human Neu Unit)/microgram protein, were used as cut-off values for c-erbB-2 ,20.2% of endometrial hyperplasia and 56.3% of endometrial carcinoma showed raised levels of the corresponding parameters.
33660848 IDO benign and malignancy AUC = 0.733, 95% CI, 0.602-0.840, p<0.002 Receiver operating characteristic curve analysis revealed that IDO was good predictors of early-stage endometrial cancer
8317901 sIL-2R controls and malignancy p<0.05 Serum sIL-2R levels were higher in the 35 patients with endometrial cancer than in the 102 patients with benign uterine diseases.
7740849 cathepsin D controls and malignancy A significant higher level of Cathepsin D expression was found in endometrial carcinoma (median value = 24.2 pmol/mg) compared to normal endometrium (median value = 11.4 pmol/mg).
7737582 CA125 II discrimination The examination by the receiver operating characteristic curve revealed that CA125 II has higher precision than that of CA125 when it is used for the screening test.
1427403 Plasminogen activator inhibitor-type 2 (PAI-2) controls and malignancy p<0.01 PAI-2 was detectable in four of seven normal endometrial homogenates at low concentrations (range, 1.1-3.1; median, 1.1 ng/mg protein) and in all malignant tissue homogenates at significantly higher levels (range, 1.6-27.3; median, 4.9 ng/mg protein),
27898420 BANCR controls and malignancy (type 1 EC) p<0.01 QRT-PCR revealed that the expression of lncRNA BANCR was signiϐicantly higher in type 1 EC tissues (9.002±1.303) than that in normal endometrium tissues (2.2͹9±0.6072)
32173521 CCAT1 controls and malignancy (type 1 EC) p<0.05 Median expression of CCAT1 was observed to be notably (9.3-fold) elevated in type 1 endometrial cancer when compared to normal endometrial tissue
33660848 periostin benign and malignancy AUC = 0.668, 95% CI, 0.533-0.785, p=0.018 Receiver operating characteristic curve analysis revealed that periostin was good predictors of early-stage endometrial cancer
28700435 CD10 controls and malignancy p=0.001 CD10 was preferentially expressed in ESS compared with smooth muscle tumors
34420090 CTNNB1 beta-catenin predictive CTNNB1 mutation Nuclear beta-catenin and LEF1 were significantly associated with CTNNB1 mutation, showing nuclear beta-catenin a better specificity and positive predictive value for CTNNB1 mutation
33436780 HE4 benign and malignancy Using the non-EC group as the reference population, the obtained area under the ROC curve (AUC) of HE4 for diagnosing EC was 0.7023 (χ2 = 30.951, P < 0.001;
33436780 HE4 different pathological types For different pathological types, the critical value was 30.60 mmol/L, and the sensitivity and specificity were 93.85% and 33.33%,
33436780 HE4 discrimination χ2 = 30.049 p<0.001 The EC, uterine leiomyoma, endometrial polyp, ovarian cyst, and uterine prolapse groups showed significant differences in serum HE4 levels
33436780 HE4 benign and malignancy AUC=0.7023; χ2 = 30.951 p<0.001 Using the non-EC group as the reference population, the obtained area under the ROC curve (AUC) of HE4 for diagnosing EC was 0.7023
33419819 NLR discrimination Area under curve (AUC) values were 0.608,NLR = 3.88 — sensitivity 80.6% and specificity 42.39%
33419819 PLB discrimination Area under curve (AUC) values were 0,613 for PLR ,PLR = 231.3 — sensitivity 80.6% and specificity 42.39%
33360772 C22-ceramides benign and malignancy sensitivity=67%
33360772 C22-ceramides benign and malignancy specificity=81%
33360772 C22-ceramides benign and malignancy AUC=0.77%
28700435 CD10 controls and malignancy p=0.001 CD10 was preferentially expressed in low-grade ESS compared with leiomyomas
33360772 C16-ceramide benign and malignancy sensitivity=73%
34418427 PR+p53 discrimination AUC = 0.92; 95%CI = 0.88-0.95 A practical two-biomarker panel with PR and p53 improved diagnostic accuracy
33360772 C16-ceramide benign and malignancy specificity=81%
33360772 C16-ceramide benign and malignancy AUC=0.83
33360772 hydroxyhexadecenoylcarnitine benign and malignancy sensitivity=60%
33360772 hydroxyhexadecenoylcarnitine benign and malignancy specificity=96%
33360772 hydroxyhexadecenoylcarnitine benign and malignancy AUC=0.76
33360772 1-methyladenosine benign and malignancy sensitivity=0.67
33360772 1-methyladenosine benign and malignancy specificity=81%
33360772 1-methyladenosine benign and malignancy AUC=0.75
28700435 IFITM1 controls and malignancy p=0.006 IFITM1 showed increased staining in carcinosarcoma group compared with leiomyosarcoma (intensity
33360772 C22-ceramides+C16-ceramide+hydroxyhexadecenoylcarnitine+1-methyladenosine benign and malignancy sensitivity =94%
33360772 C22-ceramides+C16-ceramide+hydroxyhexadecenoylcarnitine+1-methyladenosine benign and malignancy specificity=75%
34418427 PR, IMP3, and L1CAM histological subtype AUC = 0.93; 95%CI = 0.88-0.98 In preoperative high-grade EC, the diagnostic accuracy of histological subtype was improved by a three-immunohistochemical biomarker panel (PR, IMP3, and L1CAM)
33360772 C22-ceramides+C16-ceramide+hydroxyhexadecenoylcarnitine+1-methyladenosine benign and malignancy CI 90.5–94.5% AUC=92.5%
33323854 folate receptor alpha serous and high-grade endometrioid carcinoma Serous and high-grade endometrioid carcinomas are the most common carcinomatous components of CSs and are known to show consistently high FRA expression.
33208911 LGALS3BP benign and malignancy 95% CI: 0.6506–0.8305 The AUC of plasma exosomal LGALS3BP was 0.7406
33197888 PPARγ(-)/ERRα(+) benign and malignancy Youden index=0.6633 p<0.001 AUC=0.915
33197888 PPARγ(-)/ERRα(+) benign and malignancy Youden index=0.6633 p<0.001 A PPARγ/ERRα ratio≤1.86 area under the ROC curve (AUC)=0.915
33143739 GHSR healthy controls and malignancy (0.90–1.00) Full void urine AUC=0.95
33143739 SST healthy controls and malignancy Full void urine AUC=0.92
34086554 microRNA 21 discrimination 95% CI = 74.7 - 94.5 The sensitivity was 84.51%
33143739 ZIC1 healthy controls and malignancy Full void urine AUC=0.86
33099933 CA72-4 + CA15.3 healthy controls and malignancy p<0.001 CA72-4 and CA15.3 increased dramatically in cancer patients
33099933 CA72-4 + CA15.3 healthy controls and malignancy p<0.001 CA72-4 and CA15.3 were closely related to the occurrence of gynecologic malignancies
34410950 cytoplasmic LCOR benign and malignancy U=486 p<0.0001 The semi-quantitative immunoreactive score values were higher in carcinomas compared to control tissues for cytoplasmic LCOR(1median IRS 1.0 and 0.0 for cancer and control tissues, respectively)
33059604 MCM5 discrimination Using a cut off of 12 pg/mL, overall sensitivity for endometrial cancer was 87.8
33059604 MCM5 healthy controls and malignancy p<0.0001 Median levels were higher in the urine samples from cancer patients (17.60 pg/mL) compared to controls (2.81 pg/mL),
32920817 [ER + PR]/[P53 + Ki67] discrimination The ROC curve showed that 0.92 was the optimal cut-off value of the ratio ([ER + PR]/[P53 + Ki67]).
32711295 HE4 discrimination 95 % confidence interval [CI]: 0.63-0.67 The pooled sensitivity was 0.65
32711295 HE4 discrimination 95 % CI: 0.92-0.95 SPE was 0.913
32711295 HE4 discrimination 95 % CI: 4.75-21.35 PLR was 10.06
28700435 IFITM1 controls and malignancy p=0.004 IFITM1 showed increased staining in carcinosarcoma group compared with leiomyosarcoma
32711295 HE4 discrimination 95 % CI: 0.33-0.50) NLR was 0.41
32711295 HE4 discrimination 95 % CI: 11.7-60.93 diagnostic odds ratio (DOR) was 26.7
32711295 HE4 discrimination 95 % CI: 0.81-0.87 the area under curve (AUC) of the receiver operating characteristic curve (SROC) curve was 0.75
32703491 p53 discrimination Thirteen observational studies with 727 endometrial cancers were included. Both "overexpression" and "overexpression or complete absence" showed high diagnostic accuracy (AUC = 0.9088 and 0.9030)
34399708 rs1137101 benign and malignancy Heterozygous genotype AG of SNP LEP-R c.668A>G (p.Gln223Arg, rs1137101) is statistically less frequent in women with endometrial cancer (EC) than in controls:
32703491 p53 discrimination The subgroup with "overexpression" and :next generation sequencing showed the best results, with very high diagnostic accuracy(AUC = 0.9927)
30684972 RRBP1 healthy controls and malignancy p<0.05 RRBP1 was more highly expressed in endometrial cancer samples than in normal sample
30683081 SNF5 healthy controls and malignancy p<0.01 The expression of SNF5 was dramatically increased in EC compared with the normal endometrium
30618036 monocyte-macrophage-derived MPs healthy controls and malignancy p<0.001 The total amount of TF+ MPs was much higher in the EC group than controls (3381 [2410–5925];
30618036 monocyte-macrophage-derived MPs healthy controls and malignancy p<0.0001 The amount of monocytic MPs was higher in EC patients than healthy controls (402 [126–3188]
28624692 YKL-40 controls and malignancy p<0.00001 The Mann-Whitney test performed in all patients with endometrial cancer revealed significantly increased serum concentrations of YKL-40; compared to the control group of healthy women
30618036 monocyte-macrophage-derived MPs healthy controls and malignancy p<0.0027 The total amount of circulating MPs was higher in uterine blood (7542 [3687–10745]
30618036 monocyte-macrophage-derived MPs healthy controls and malignancy p<0.0001 The amount of monocytic MPs was higher in EC patients than healthy controls (402 [126–3188];
30614088 IMP3 discrimination Only ESC cases showed strong immunoreactivity (≥3+) in more than 50% of tumour cells with an average frequency of 80%
30614088 IMP3 discrimination The ESC samples showed positive staining cells in 100%, EAC-3 in 28.5%, and EAC-1 in 2.4% cases
30585737 miR-142 healthy controls and malignancy p<0.001 qPCR was employed to test whether miR-142 was associated with EC progress, and the data showed that there was much lower mRNA level of miR-142 in tumor tissues of EC patients compared with matched normal tissues
34331128 microRNA-21 cancer cell and stroma cell hazard ratio=2.460 p=0.041 Multivariate analysis high miR-21 expression in cancer cells
30556848 LncRNA FER1L4 healthy controls and malignancy p<0.01 FER1L4 in EC tissues was significantly down-regulated compared with adjacent non-tumor tissues
30508211 CA125 LNM 95% confidence interval: 0.481–0.831 p=0.077 Preoperative CA125 predictable for LNM AUC was 0.656
30414437 HE4 discrimination 0.71 (95%CI 0.56-0.82) The pooled estimates for HE4 was sensitivity:
30414437 HE4 discrimination 0.87 (95%CI 0.80-0.92), The pooled estimates for HE4 was specificity
28624692 YKL-40 benign and stage I-IB p<0.00002 The Mann-Whitney test performed in patients with stage I-IB revealed significantly increased serum concentrations of YKL-40; compared to the control group of healthy women.
30414437 HE4 discrimination 0.88 (0.85-0.91) The pooled estimates for HE4 were rea under ROC curve
30377136 MMP20 healthy controls and malignancy p=0.00065 Real-time PCR analysis confirmed the up-regulated expressions of MMP20 at the mRNA levels in endometrial carcinoma tissues compared to the adjacent endometrial tissues
30377136 MMP20 healthy controls and malignancy p=0.005 Immunohistochemistry confirmed the up-regulated expressions of MMP20 at protein levels in endometrial carcinoma tissues compared to the adjacent endometrial tissues.
30374843 Autotaxin pelvic organ prolapse control group and malignancy p=0.0002 ATX expression levels were significantly higher in endometrial cancer compared with control samples
29984790 MACC1 controls and malignancy p<0.05 In cancer tissues, the positive rate of MACC1 or c-Myc was 73.3% and 78.3%, respectively, which were significantly higher than that in adjacent or control tissues
29984790 MACC1/c-Myc controls and malignancy p<0.05 Our data indicate that the level of serum MACC1 and c-Myc in the experimental group was 1.67±0.08 ng/ml and 1.78±0.07 ng/ml, respectively, both of which were significantly higher than that of the control group.
35076938 6-keto-PGF1α, PA(37:4), LysoPC(20:1) and PS(36:0) distinguishing EP from EH The biomarker panel for distinguishing EP from EC yielded an area under the curve (AUC) of 0.915, sensitivity of 100% and specificity of 72.41%, while that for distinguishing EP from EH yielded an AUC of 1.000, sensitivity of 100% and specificity of 100%.
35216190 SBSN controls and malignancy These data proved that SBSN was downregulated in EC tissue, where the two isoforms of the protein had a good AUC (area under the ROC curve) (isoform 1 AUC = 0.7928 and isoform 2 AUC = 0.7933)
35284957 two miRNAs (409 and 200c) and 8 CpG sites (4 CpGs at SLC22A18, 3 at HYAL2, and 1 at FUT7) controls and malignancy Malonylcarnitine distinguished best patients with EC from controls (AUC: 0.827, sens. 80%, spec. 73.1%) or BC (AUC: 0.819, sens. 84.3%, spec. 80%) being most notable. Tryptophan best differentiated benign from EC (AUC: 0.846, sens. 70%, spec. 92.9%).
3651063 2,3-Pyridinedicarboxylic acid between EC phase I versus EC phase III Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
28624692 YKL-40 controls and malignancy 95%CI:0.726- 0.900 p<0.0001 Based on the ROC curve analysis carried out in all patients vs. the control group, the cut-off point was determined for YKL-40 as above 39.1 ng/mL (sensitivity 62.2%, specificity 88%)
3651063 Hematommic acid, ethyl ester between EC phase I versus EC phase III Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
3651063 Maltitol between EC phase I versus EC phase III Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
3651063 13(S)-HODE between EC phase I versus EC phase III Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
3651063 D-Mannitol between EC phase I versus EC phase III Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
35323926 zinc finger and SCAN domain containing 12 (ZSCAN12) and/or oxytocin (OXT) controls and malignancy Hypermethylation of zinc finger and SCAN domain containing 12 (ZSCAN12) and/or oxytocin (OXT) classified EC samples from multiple noncancer samples with high diagnostic specificity/sensitivity [>97%; area under the curve (AUC) = 0.99; TCGA/GEO tissues/blood samples].
36721236 SLERT controls and malignancy P < 0.001 High SLERT was observed in EC tissues as compared to normal tissues (4.3-fold increase) (P = 0.008), with an area under of ROC (AUC) value of 0.75 (95% CI: 0.6604~0.8476) (P < 0.001).
36721236 SLERT controls and malignancy P < 0.001 SLERT was notably increased in EC plasma (3.2-fold upregulation) (P < 0.001), with an AUC value of 0.84 (95%CI: 0.7384~0.9394)
34282107 TAM nonendometrioid carcinomas P=0.0001 Epithelial TAMs counts were higher in patients with nonendometrioid carcinomas
36251972 Pirh2 controls and malignancy P =0.001 There was a significant upregulation of Pirh2 mRNA expression in EC specimens as compared with the control adjacent tissues.
34974784 YKL-40 controls and malignancy The SROC curve presented an area under the curve (AUC) of 0.853 (SE = 0.0213) for YKL-40 alone and an AUC of 0.946 (SE = 0.0268) for YKL-40 combined with other biomarkers.
29936727 neutrophil lymphocyte ratio (NLR) controls and malignancy p=0.033 The NLR value for the endometrial adenocarcinoma group was significantly higher than for the control group
28624692 YKL-40 controls and malignancy 95% CI: 0.702– 0.907 p<0.0001 Determined YKL-40 concentration cut-off point of above 35.5 ng/mL (AUC = 0.804,sensitivity 68.9%, specificity 80%) was able to accurately differentiate between healthy individuals and patients in the early stages of the disease.
36788073 SOX17 controls and malignancy In summary, our results demonstrate that SOX17 is a sensitive and specific marker for ovarian nonmucinous carcinomas and endometrial carcinomas.
35891746 Ki-67 controls and malignancy p=0.0001 In patients with endometrial carcinoma, there was an increased expression of Ki-67, compared to proliferative endometrium and simple hyperplasia
35941559 ADC stage IA EC Multivariate analysis demonstrated that ADC-score (ADC10th+ skewness + rMAD + total energy) was the only significant independent predictor (OR = 2.641, 95% CI 2.045-3.411; p < 0.001) for stage IA EC when considering clinical parameters.
36751747 miR-16 controls and malignancy P<0.05 In endometrioid EC, miR-16, miR-99b, miR-125 and miR-145 were downregulated (P<0.05), whereas miR-143 was upregulated (P<0.05).
36751747 miR-99b controls and malignancy P<0.05 In endometrioid EC, miR-16, miR-99b, miR-125 and miR-145 were downregulated (P<0.05), whereas miR-143 was upregulated (P<0.05).
36751747 miR-125 controls and malignancy P<0.05 In endometrioid EC, miR-16, miR-99b, miR-125 and miR-145 were downregulated (P<0.05), whereas miR-143 was upregulated (P<0.05).
36751747 miR-145 controls and malignancy P<0.05 In endometrioid EC, miR-16, miR-99b, miR-125 and miR-145 were downregulated (P<0.05), whereas miR-143 was upregulated (P<0.05).
36751747 miR-143 controls and malignancy P<0.05 In endometrioid EC, miR-16, miR-99b, miR-125 and miR-145 were downregulated (P<0.05), whereas miR-143 was upregulated (P<0.05).
36799979 ursodeoxycholic acid, PC(O-14:0_20:4), and Cer(d18:1/18:0) controls and malignancy This panel（ursodeoxycholic acid, PC(O-14:0_20:4), and Cer(d18:1/18:0)） was assessed as an effective diagnostic model to distinguish early-stage EC patients from healthy controls and atypical endometrial hyperplasia patients within the area under the receiver operating characteristic curve (AUC) reaching 0.903 and 0.928, respectively.
35866777 KRT15 P = .010 Elevated KRT15 protein expression was correlated with the occurrence of lymphovascular invasion .
28624692 CA125 controls and malignancy p<0.00002 The Mann-Whitney test performed in all patients with endometrial cancer revealed significantly increased serum concentrations of CA125; compared to the control group of healthy women
35866777 KRT15 P < .001 KRT15 protein and mRNA expressions were higher in tumor tissue compared with adjacent tissue
36807337 SPRR1B, CRNN, CALML3, TXN, FABP5, C1RL, MMP9, ECM1, S100A7 and CFI The best performing diagnostic model was a 10-marker panel combining SPRR1B, CRNN, CALML3, TXN, FABP5, C1RL, MMP9, ECM1, S100A7 and CFI and predicted endometrial cancer with an AUC of 0.92 (0.96-0.97).
36807337 SPRR1B, CRNN, CALML3, TXN, FABP5, C1RL, MMP9, ECM1, S100A7 and CFI Urine-based protein signatures showed good accuracy for the detection of early-stage cancers (AUC 0.92 (0.86-0.9)).
36510632 2,3-Pyridinedicarboxylic acid Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
36510632 Hematommic acid, ethyl ester Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
36510632 Maltitol Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
36510632 13(S)-HODE Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
36510632 D-Mannitol Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AUC) = 0.69), Hematommic acid, ethyl ester (AUC = 0.69), Maltitol (AUC = 0.69), 13(S)-HODE (AUC = 0.88), and D-Mannitol (AUC = 0.69) had potential diagnostic ability between EC phase I versus EC phase III.
28624692 CA125 controls and malignancy p<0.0005 The Mann-Whitney test performed in patients with stage I-IB revealed significantly increased serum concentrations of CA125; compared to the control group of healthy women.IB
32848704 DJ-1 controls and malignancy p≤0.05 The median serum levels of DJ-1 in patients with EC was 730 pg/mL, significantly higher than found in control subjects
28618925 CA125 controls and malignancy p≤0.05 CA125 levels were significantly higher in EC patients compared with healthy subjects(36 vs 13 UI/L)
28618925 CA125 EEC p≤0.05 The difference in CA125 levels remains statistically significant for each EC subtype (EEC-G1 = 36 UI/L, EEC-G2 = 24 UI/L, EEC-G3 = 35 UI/L, and SEC/CCEC = 34 UI/L) compared to controls
34086554 microRNA 21 discrimination 95% CI = 74.0 - 92.0 The specificity was 86.79%
28618925 HE4 controls and malignancy p≤0.05 HE4 levels were significantly different in EC patients versus healthy controls.(77 vs 49 pmol/mL)
28618925 HE4 EC subtype VS controls p≤0.05 HE4 levels were significantly different in when each EC subtype (EEC-G1 = 77 pmol/mL, EEC-G2 = 73 pmol/mL, EEC-G3=92pmol/mL, and SEC/CCEC=79 pmol/mL) was compared to controls
28418882 EZH2 controls and malignancy p≤0.05 EZH2 expression was significantly higher in the 52 endometrial cancer tissues than in the four normal control tissues
29898448 ProGRP(Gastrin-releasing peptide) controls and malignancy 95% CI 0.667–0.882 p< 0.001 The predictive accuracy of ProGRP as a marker for EA was found by ROC curve analyses AUC=0.775
28383326 neopterin controls and malignancy p<0.001 Increased urinary neopterin levels were observed in patients with endometrial cancer
28374920 DJ-1 controls and malignancy p<.0001 Serum DJ-1 concentrations was higher in EC patients than in HC.(9533.6 vs 1988.5 pg/mL)
28374920 DJ-1 controls and malignancy p<.0001 The area under the ROC curve (ROC-AUC) was 0.95
28374920 DJ-1 controls and malignancy At the cut-off of 3654 pg/mL, the sensitivity and specificity were 0.89 and 0.90, respectively
28374920 DJ-1+HE4 controls and malignancy p<.0001 The AUC obtained by the combination of the two markers resulted 0.96
28098927 HE4 controls and malignancy p<0.001 The area under the curve (AUC) for HE4 was 0.875, suggesting that this marker reliably differentiates malignant from non-malignant endometrial pathologies
28098927 HE4 controls and malignancy p<0.001 Serum HE4 levels were significantly higher in patients with endometrial cancer (EC) as compared to non-malignant endometrial pathologies
34086554 microRNA 21 benign lesions and controls For discrimination between benign lesions and controls the AUC was 0,881 with a sensitivity of 100%
28098927 HE4 controls and malignancy p<0.001 Serum HE4 levels were significantly higher in patients with stage I EC as compared to non-malignant endometrial pathologies
28098927 HE4 controls and malignancy p=0.003 Serum HE4 levels were significantly higher in patients with stage Ia EC as compared to non-malignant endometrial pathologies
29898448 ProGRP(Gastrin-releasing peptide) benign and malignancy p=0.008 Median serum ProGRP levels were significantly higher in the cancer group compared to corresponding levels in the hyperplasia
28098927 HE4 controls and malignancy Sensitivity and specificity of HE4 at the cut-off level of 70 pmol/L for detecting endometrial malignancies were 73.08% and 85.71%
27918216 S100P controls and malignancy Much higher S100P level was detected in each of the endometrial squamous (one case, 3.23%) and adenosquamous carcinomas (12 cases, 38.71%) samples than those in normal controls or in endometrial adenocarcinoma samples
27902476 p16 between AH/EIN and SEIC p=0.001 There was a significant difference in stromal p16 expression status between AH/EIN and SEIC
27902476 p16 SC vs EC p=0.021 Stromal p16 expression levels were significantly higher in SC than in EC
27902476 p16 controls and malignancy p<0.001 A significant difference was observed in stromal p16 expression between the benign and precancerous lesions
27902476 p16 precancerous VS malignancy p =0.005 Stromal p16 expression differed significantly between the precancerous and malignant groups
27902476 p16 controls and malignancy p<0.001 AH/EIN exhibited significantly higher levels of stromal p16 expression compared with hyperplasia without atypia
27902476 p16 controls and malignancy p=0.012 A significant difference was also noted in stromal p16 expression when comparing EC with AH/EIN
34086554 microRNA 21 benign lesions and controls 100% (95% CI = 93.4 - 100.0) sensitivity benign lesions VS controls
27634881 HIF-1α premalignant lesions VS low grade endometrioid EC lesions p<0.001 High HIF-1α expression in stromal cells were almost non-existing in premalignant lesions, but was frequently observed in low grade endometrioid EC lesions
29898448 ProGRP(Gastrin-releasing peptide) discrimination p<0.001 Median serum ProGRP levels were significantly higher in the cancer group compared to corresponding levels in control groups
27562869 Combination of HE4, CA125, CA724, and CA19-9 controls and malignancy p<.001 Serum HE4, CA125, CA724, and CA19-9 concentrations were significantly higher in patients with endometrial cancer, compared with controls
27540975 UCA1 lymph node metastasis VS proliferative endometrium and primary EC tissues p<0.0001 The expression level of UCA1 using QRT-PCR method in lymph node metastasis tissue was the highest than that in the proliferative endometrium and primary EC tissues.(1.15 ± 0.23, 3.23 ± 1.06 vs. 6.42 ± 1.46)
27512000 GGT controls and malignancy p<0.001 Comparable high GGT median apical expression was confirmed in healthy endometrium (2.0, S.E.M. = 0.28) and in G1-2 EAC (2.0, S.E.M. = 0.27)
27340318 IL-31 controls and malignancy p<0.0001 The serum levels of IL-31 in the patients were dramatically higher than the counterparts of the controls(sensitivity: 92.68%, specificity: 94.87%)
27340318 IL-31 controls and malignancy 95% CI: 0.945–0.998 p<0.0001 The serum levels of IL-33 in the patients were dramatically higher than the counterparts of the controls
27340318 IL-31 controls and malignancy 95% CI: 0.945–0.998 p<0.0001 The cut-off value of serum IL-31 was about 113.1 pg/mL (sensitivity: 92.68%, specificity: 94.87%) and the area under the ROC curve (AUC) of IL-31 was 0.973
27340318 IL-33 controls and malignancy 95% CI: 0.86–0.998 p<0.0001 The best cut-off value of serum IL-33 was about 98.42 pg/mL (sensitivity: 88.64%, specificity: 97.22%); the AUC was 0.929
27268621 HE-4 controls and malignancy p<0.001 Mean serum HE-4 levels were significantly higher in endometrium cancer group; 892 pmol/L versus 467 pmol/L
27268621 HE-4 controls and malignancy A cut off value of 458 pmol/L was predictive of malignancy with 86% sensitivity and 63% specificity.
34086554 microRNA 21 benign lesions and controls 66.04% (95% CI = 51.7 - 78.5) specificity benign lesions VS controls
29848072 miR-29b The best diagnostic threshold value of miR-29b in the peripheral blood was 0.940 . The sensitivity (96.1%) and the specificity (97.9%) had a certain value for the diagnosis of EC
27226215 PAX1 premalignant endometrial lesions VS malignancy p<0.001 The PAX1 protein score was significantly higher in samples of premalignant endometrial lesions compared with those of EC
27177284 miR-887-5p sera(controls and malignancy ) p<0.05 Expression of miR-887-5p was significantly increased in the sera of patients with endometrial cancer compared with that in the sera of healthy subjects
27177284 miR-887-5p controls and malignancy 95% CI 0.563-0.892 Receiver operating characteristic curve analysis showed that the area of miR-887-5 under the ROC curve for endometrial cancer diagnosis was 0.728, specificity was 0.60, sensitivity was 0.95
27124937 IFITM1 invasive vs noninvasive areas. p<.0001 Unlike CD10, IFITM1 staining showed significant differences in mean intensity (P < .0001) and distribution between invasive vs noninvasive areas.
27079858 clusterin controls and malignancy p=0.019 Significant difference in clusterin expression was observed between tumor cases and control group
26985869 MIF controls and malignancy p=0.03 The positive rates of MIF protein in NE, atypical hyperplasia and EC were 20, 45 and 70%, respectively
26959119 S18-2 controls and malignancy p<0.05 We observed a significant difference in S18-2 expression in all EC samples and in HP and NE samples combined
26959119 E2F1 controls and malignancy p<0.05 In all tumors E2F1 showed a significantly higher signal than in hyperplasia or normal endometrium.
26839161 Nup88 controls and malignancy p<0.001 Nup88 expression in cancer (76%) and atypical hyperplasia (91%) was higher compared to normal endometrium (33%).
26607777 HE-4 controls and malignancy p<0.001 Preoperative serum HE-4 levels were significantly higher in endometrial cancer group.(AUC = 0.882)
29848072 miR-29b The best diagnostic threshold value of miR-29b in PB was 0.917. The sensitivity (96.7%) and the specificity (95.0%) had a high value for EC diagnosis.
34086554 microRNA 21 benign lesions and controls benign lesions VS tumors(AUC=0.750)
26607777 YKL-40 controls and malignancy p<0.001 Preoperative serum  YKL-40 levels were significantly higher in endometrial cancer group(AUC = 0.823)
26607777 CA125 controls and malignancy p<0.001 Preoperative serum CA125 levels were significantly higher in endometrial cancer group
26539494 HE4 controls and malignancy p=0.014 The positive expression rate of HE4 was 84.62% in the endometrial cancer group, significantly higher than 66.67% in the endometrial atypical hyperplasia group,
26539494 HE4 controls and malignancy p=0.001 The positive expression rate of HE4 was 84.62% in the endometrial cancer group, significantly higher than 15.00% in the normal endometrium group
26539494 HE4 atypical hyperplasia p=0.045 The positive rate of HE4 expression in the moderate and severe atypical hyperplasia groups was significantly higher than that in the mild atypical hyperplasia group
26539494 HE4 hyperplasia VS normal control p<0.001 The positive rate of HE4 expression in the moderate and severe atypical hyperplasia groups was significantly higher than that in the normal endometrium group
26539494 HE4 controls and malignancy p=0.003 The strongly positive (2+/3+) expression rate in endometrial cancer was 55.98%, significantly higher than that in the atypical hyperplasia group (20.00%)
26539494 HE4 controls and malignancy p=0.033  The strongly positive (2+/3+) expression rate in endometrial cancer was 55.98%, significantly higher than that in the normal endometrium group
26539494 HE4 atypical hyperplasia p=0.025 The strongly positive expression rate of HE4 in the severe hyperplasia group was significantly higher than that in the mild hyperplasia group

Institutes for Systems Genetics, West China Hospital
     Copyright @ 2023 ISG. All Rights Reserved.